CR20240493A - Proteínas de fusión de hmpv de prefusión estabilizadas - Google Patents

Proteínas de fusión de hmpv de prefusión estabilizadas

Info

Publication number
CR20240493A
CR20240493A CR20240493A CR20240493A CR20240493A CR 20240493 A CR20240493 A CR 20240493A CR 20240493 A CR20240493 A CR 20240493A CR 20240493 A CR20240493 A CR 20240493A CR 20240493 A CR20240493 A CR 20240493A
Authority
CR
Costa Rica
Prior art keywords
fusion proteins
hmpv
hmpv fusion
stabilized prefusion
stabilized
Prior art date
Application number
CR20240493A
Other languages
English (en)
Spanish (es)
Inventor
Johannes Petrus Maria Langedijk
Tina Ritschel
Jaroslaw Juraszek
Mark Johannes Gerardus Bakkers
Original Assignee
Msd Int Business Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msd Int Business Gmbh filed Critical Msd Int Business Gmbh
Publication of CR20240493A publication Critical patent/CR20240493A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CR20240493A 2022-05-12 2023-05-11 Proteínas de fusión de hmpv de prefusión estabilizadas CR20240493A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22173131 2022-05-12
PCT/EP2023/062652 WO2023217988A1 (en) 2022-05-12 2023-05-11 Stabilized pre-fusion hmpv fusion proteins

Publications (1)

Publication Number Publication Date
CR20240493A true CR20240493A (es) 2025-01-29

Family

ID=81653543

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20240493A CR20240493A (es) 2022-05-12 2023-05-11 Proteínas de fusión de hmpv de prefusión estabilizadas

Country Status (16)

Country Link
EP (1) EP4522209A1 (enExample)
JP (1) JP2025521082A (enExample)
KR (1) KR20250010642A (enExample)
CN (1) CN119562826A (enExample)
AU (1) AU2023269241A1 (enExample)
CA (1) CA3253332A1 (enExample)
CL (1) CL2024003418A1 (enExample)
CO (1) CO2024015386A2 (enExample)
CR (1) CR20240493A (enExample)
DO (1) DOP2024000230A (enExample)
GE (1) GEAP202516650A (enExample)
IL (1) IL316911A (enExample)
JO (1) JOP20240256A1 (enExample)
MX (1) MX2024013959A (enExample)
PE (1) PE20251395A1 (enExample)
WO (1) WO2023217988A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026504862A (ja) 2023-01-18 2026-02-10 ファイザー・インク 呼吸器疾患に対するワクチン
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2025144636A1 (en) * 2023-12-26 2025-07-03 The Scripps Research Institute ENGINEERED hMPV F PROTEIN IMMUNOGENS AND RELATED VACCINES
WO2025163460A2 (en) * 2024-01-30 2025-08-07 Pfizer Inc. Vaccines against respiratory diseases
WO2026018181A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
PL215165B1 (pl) 2002-04-25 2013-10-31 Crucell Holland Bv Rekombinowany wektor adenowirusowy oraz sposób wytwarzania rekombinowanego wektora adenowirusowego
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
JP7382230B2 (ja) 2016-10-17 2023-11-16 ヤンセン ファーマシューティカルズ，インコーポレーテッド 組み換えウイルスレプリコン系及びその使用
BR112019011661A2 (pt) 2016-12-05 2020-01-07 Synthetic Genomics, Inc. Composições e métodos para aumentar expressão de gene
US12559544B2 (en) * 2019-05-21 2026-02-24 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use
CN116615235A (zh) * 2020-10-09 2023-08-18 得克萨斯州大学系统董事会 融合前稳定的hmpv f蛋白

Also Published As

Publication number Publication date
CA3253332A1 (en) 2023-11-16
CL2024003418A1 (es) 2025-08-01
JOP20240256A1 (ar) 2024-11-11
AU2023269241A1 (en) 2024-11-21
WO2023217988A1 (en) 2023-11-16
IL316911A (en) 2025-01-01
MX2024013959A (es) 2025-02-10
CO2024015386A2 (es) 2024-11-28
DOP2024000230A (es) 2025-02-16
GEAP202516650A (en) 2025-03-10
CN119562826A (zh) 2025-03-04
JP2025521082A (ja) 2025-07-08
KR20250010642A (ko) 2025-01-21
PE20251395A1 (es) 2025-05-22
EP4522209A1 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
MX2024013959A (es) Proteinas de fusion del hmpv estabilizadas por prefusion
EA201391632A1 (ru) Аминокислотные последовательности, направленные против il-17a, il-17f и/или il-17a/f, и содержащие их полипептиды
MX2022006760A (es) Composiciones de proteina anti-vegf y metodos para producir la misma.
CY1120670T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi)
CR20110245A (es) Mutantes fgf21 y uso de los mismos.
EA201270062A1 (ru) Вакцина
DE602007008360D1 (de) Aviäre telomerase reverse transkriptase
MX2020012350A (es) Anticuerpos anti-cd63, conjugados y usos de estos.
CL2011003122A1 (es) Anticuerpo que se une a la proteina tau fosforilada en la serina 422 (tau ps422), pero no se une a la tau ni al fragmento mcak fosforilado; acido nucleico que lo codifica; metodo de produccion; composicion farmaceutica; y uso util en el tratamiento de una tauopatia, tal como la enfermedad de alzheimer.
UY31533A1 (es) Moleculas de enlace al receptor humano ox40
EA201892561A1 (ru) Гибридные белки gdf15 и их применение
MX381183B (es) Proteínas de fusión de serpina-fc de inmunoglobulina de humano y método de purificación de las mismas.
FI3936521T3 (fi) Heterodimeerisiä proteiineja
GT201000148A (es) Anticuerpos antimesotelina y usos de los mismos
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
UY32501A (es) Anticuerpo antagonista específico para el heterodímero alfa4-beta7
CY1116336T1 (el) Αντισωματα εναντι ανασυνδυασμενης γλυκοπρωτεϊνης vi του υποδοχεα αιμοπεταλιων κολλαγονου
BR112015022210A8 (pt) formulações de anticorpo
MX2023011629A (es) Proteinas piv3 f prefusion estabilizadas.
BR112022022937A2 (pt) Proteínas de fusão estabilizadas de proteína de pico de coronavírus
EA201891141A1 (ru) Новые антиангиогенные слитые полипептиды
MX2022003811A (es) Determinacion no invasiva de glucosa.
EP2496608A4 (en) FUSION PROTEIN FOR THE SPECIFIC BINDING OF CONSTANT ANTIBODY REGIONS, PREPARATION THEREOF, AND METHOD FOR THE ANTIBODY INSULATION THEREWITH
BR112017022076A2 (pt) fusões de mesotelina-variante iii de receptor de fator de crescimento epidérmico e métodos de uso das mesmas
BR112013011015A2 (pt) formas sólidas de ácido (s)-2-amino-3-(4-(2-amino-6-((r)-1-(4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2-trifluoroetóxi)pirimidin-4-il)fenil)propanoico